{"id":31182,"date":"2023-06-30T01:16:02","date_gmt":"2023-06-29T23:16:02","guid":{"rendered":"http:\/\/www.infokuryr.cz\/n\/?p=31182"},"modified":"2023-06-29T20:40:04","modified_gmt":"2023-06-29T18:40:04","slug":"evropska-lekova-agentura-varuje-ze-lek-proti-cukrovce-zvysuje-riziko-rakoviny-stitne-zlazy","status":"publish","type":"post","link":"https:\/\/www.infokuryr.cz\/n\/2023\/06\/30\/evropska-lekova-agentura-varuje-ze-lek-proti-cukrovce-zvysuje-riziko-rakoviny-stitne-zlazy\/","title":{"rendered":"Evropsk\u00e1 l\u00e9kov\u00e1 agentura varuje, \u017ee l\u00e9k proti cukrovce zvy\u0161uje riziko rakoviny \u0161t\u00edtn\u00e9 \u017el\u00e1zy"},"content":{"rendered":"
<\/div>\n

Evropsk\u00e1 l\u00e9kov\u00e1 agentura (EMA) vydala tento t\u00fdden upozorn\u011bn\u00ed o bezpe\u010dnosti l\u00e9k\u016f p\u0159edepisovan\u00fdch na cukrovku 2. typu a obezitu, kter\u00e9 potenci\u00e1ln\u011b zvy\u0161uj\u00ed riziko vzniku rakoviny \u0161t\u00edtn\u00e9 \u017el\u00e1zy.<\/strong><\/p>\n

Semaglutid, \u00fa\u010dinn\u00e1 l\u00e1tka nach\u00e1zej\u00edc\u00ed se v \u0161iroce pou\u017e\u00edvan\u00fdch l\u00e9c\u00edch proti cukrovce a obezit\u011b jako jsou nap\u0159\u00edklad l\u00e9ky z n\u00e1zvy Ozempic, Wegovy a Rybelsus, je spojov\u00e1na se zv\u00fd\u0161en\u00fdm rizikem rakoviny \u0161t\u00edtn\u00e9 \u017el\u00e1zy u pacient\u016f, kte\u0159\u00ed u\u017e\u00edvaj\u00ed tyto l\u00e9ky podle p\u0159edpisu l\u00e9ka\u0159e.<\/span><\/p>\n

Tyto l\u00e9\u010div\u00e9 p\u0159\u00edpravky, zn\u00e1m\u00e9 jako \u201eagonist\u00e9 receptoru glukagonu podobn\u00e9ho peptidu-1\u201c (GLP-1), vyr\u00e1b\u011bj\u00ed spole\u010dnosti Novo Nordisk, AstraZeneca, Eli Lilly a Sanofi Winthrop, p\u0159i\u010dem\u017e v\u0161echny o nich mus\u00ed do 26. \u010dervence 2023 p\u0159edlo\u017eit EMA dopl\u0148uj\u00edc\u00ed informace.<\/span><\/p>\n

Upozorn\u011bn\u00ed EMA na mo\u017en\u00e9 bezpe\u010dnostn\u00ed riziko nemus\u00ed nutn\u011b znamenat p\u0159\u00edmou p\u0159\u00ed\u010dinnou souvislost mezi l\u00e9kem a hl\u00e1\u0161enou ne\u017e\u00e1douc\u00ed ud\u00e1lost\u00ed.\u00a0EMA jej pou\u017e\u00edv\u00e1 k tomu, aby pomohla l\u00e9pe ur\u010dit, zda existuje \u010di neexistuje p\u0159\u00ed\u010dinn\u00e1 souvislost, a to tak, \u017ee zkoum\u00e1 cokoliv, co j\u00ed v\u00fdrobci l\u00e9k\u016f po\u0161lou jako sou\u010d\u00e1st dopl\u0148kov\u00e9ho informa\u010dn\u00edho po\u017eadavku.<\/span><\/p>\n

\u201eSpole\u010dnost Novo Nordisk si je v\u011bdoma upozorn\u011bn\u00ed a po\u017eadavk\u016f EMA a poskytne d\u016fkladn\u00e9 vyhodnocen\u00ed v\u0161ech relevantn\u00edch \u00fadaj\u016f k objasn\u011bn\u00ed tohoto t\u00e9matu,\u201c<\/span><\/em>\u00a0uvedl Lars Otto Andersen-Lange, \u0159editel pro styk s m\u00e9dii v Novo Nordisk.<\/span><\/p>\n

Andersen-Lange dodal, \u017ee v\u0161echny souvisej\u00edc\u00ed produkty spole\u010dnosti Novo Nordisk, v\u010detn\u011b semaglutidu, jsou na trhu ji\u017e v\u00edce ne\u017e desetilet\u00ed a \u017ee \u00fadaje o bezpe\u010dnosti shrom\u00e1\u017ed\u011bn\u00e9 z postmarketingov\u00e9ho dohledu nad l\u00e9ky neprok\u00e1zaly \u017e\u00e1dn\u00e9 \u201ep\u0159esv\u011bd\u010div\u00e9\u201c d\u016fkazy, kter\u00e9 by je spojovaly s rakovinou \u0161t\u00edtn\u00e9 \u017el\u00e1zy.<\/span><\/p>\n

(Souvisej\u00edc\u00ed: Zachytili jste na\u0161i\u00a0<\/span>d\u0159\u00edv\u011bj\u0161\u00ed zpr\u00e1vu<\/span><\/a>\u00a0o tom, jak dnes l\u00e9ka\u0159i zab\u00edjej\u00ed v\u00edce lid\u00ed ne\u017e rakovina?)<\/span><\/p>\n

Velk\u00e9 farmaceutick\u00e9 firmy kritizuj\u00ed v\u00fdzkumn\u00edky za odhalen\u00ed rizika rakoviny \u0161t\u00edtn\u00e9 \u017el\u00e1zy u l\u00e9k\u016f proti cukrovce a obezit\u011b \u2013 tvrd\u00ed, \u017ee jejich studie obsahuje \u201ed\u016fle\u017eit\u00e1 omezen\u00ed\u201c<\/span><\/h2>\n

Jako obvykle, spole\u010dnost Novo Nordisk a dal\u0161\u00ed farmaceutick\u00e9 firmy odpov\u011bdn\u00e9 za v\u00fdrobu rizikov\u00fdch l\u00e9k\u016f nad\u00e1le pop\u00edraj\u00ed, \u017ee jejich produkty jsou jak\u00fdmkoli zp\u016fsobem nebezpe\u010dn\u00e9.<\/span><\/p>\n

Ve skute\u010dnosti za\u0161li dokonce tak daleko, \u017ee se zam\u011b\u0159ili na novou studii odhaluj\u00edc\u00ed souvislost ohledn\u011b mo\u017en\u00e9ho rizika rakoviny s tvrzen\u00edm, \u017ee obsahuje \u201ed\u016fle\u017eit\u00e1 omezen\u00ed\u201c.<\/span><\/p>\n

\"\"<\/a><\/p>\n

N\u011bkter\u00e9 z \u201ed\u016fle\u017eit\u00fdch omezen\u00ed\u201c, kter\u00e9 zd\u016fraznil Andersen-Lange, zahrnuj\u00ed absenci ov\u011b\u0159en\u00e9 identifikace p\u0159\u00edpadu, neadekv\u00e1tn\u00ed diferenciaci opakuj\u00edc\u00edch se ud\u00e1lost\u00ed, potenci\u00e1ln\u00ed nespr\u00e1vnou klasifikaci ud\u00e1lost\u00ed a nepotvrzenou expozici drog\u00e1m, pokud m\u00e1me citovat jeden medi\u00e1ln\u00ed zdroj.<\/span><\/p>\n

Jedn\u00e1 se o pr\u016fkopnickou studii francouzsk\u00fdch v\u00fdzkumn\u00edk\u016f, kte\u0159\u00ed se zab\u00fdvali \u00fadaji z datab\u00e1ze francouzsk\u00e9ho n\u00e1rodn\u00edho syst\u00e9mu zdravotn\u00edho poji\u0161t\u011bn\u00ed.\u00a0P\u0159i anal\u00fdze dat si v\u0161imli zv\u00fd\u0161en\u00e9ho rizika rakoviny \u0161t\u00edtn\u00e9 \u017el\u00e1zy u jedinc\u016f, kte\u0159\u00ed u\u017e\u00edvaj\u00ed p\u0159\u00edslu\u0161n\u00e9 l\u00e9ky, zejm\u00e9na mezi prvn\u00edm a t\u0159et\u00edm rokem jejich u\u017e\u00edv\u00e1n\u00ed.<\/span><\/p>\n

\u010casopis\u00a0<\/span>Diabetes Care<\/span><\/em>\u00a0\u00fadajn\u011b zve\u0159ejnil dva koment\u00e1\u0159e ke studii, z nich\u017e jeden nazna\u010duje, \u017ee \u201edetek\u010dn\u00ed zaujatost\u201c by mohla zp\u016fsobit, \u017ee l\u00e9ky zp\u016fsobuj\u00ed rakovinu \u0161t\u00edtn\u00e9 \u017el\u00e1zy, i kdy\u017e ve skute\u010dnosti nezp\u016fsobuj\u00ed.\u00a0Druh\u00fd nazna\u010duje, \u017ee studie m\u016f\u017ee b\u00fdt neplatn\u00e1, proto\u017ee nezohlednila obezitu jako matouc\u00ed faktor p\u0159i rakovin\u011b \u0161t\u00edtn\u00e9 \u017el\u00e1zy.<\/span><\/p>\n

Je zaj\u00edmav\u00e9, \u017ee informace o p\u0159edepisov\u00e1n\u00ed l\u00e9k\u016f Ozempic a Wegovy od spole\u010dnosti Novo Nordisk obsahuj\u00ed varov\u00e1n\u00ed o riziku vzniku n\u00e1dor\u016f C-bun\u011bk \u0161t\u00edtn\u00e9 \u017el\u00e1zy.<\/span><\/p>\n

V\u00fdrobce tak\u00e9 v literatu\u0159e o p\u0159edepisov\u00e1n\u00ed l\u00e9ku uv\u00e1d\u00ed, \u017ee \u00fa\u010dinn\u00e1 l\u00e1tka semaglutid je spojen s \u201en\u00e1dory C-bun\u011bk \u0161t\u00edtn\u00e9 \u017el\u00e1zy z\u00e1visl\u00fdmi na d\u00e1vce a trv\u00e1n\u00ed l\u00e9\u010dby\u201c u hlodavc\u016f, ale \u017ee lidsk\u00e9 rakoviny z\u016fst\u00e1vaj\u00ed \u201enezji\u0161t\u011bny\u201c.<\/span><\/p>\n

Z\u00e1v\u011br<\/span><\/h2>\n

Ty, kte\u0159\u00ed maj\u00ed v rodinn\u00e9 anamn\u00e9ze rakovinu \u0161t\u00edtn\u00e9 \u017el\u00e1zy, varuje americk\u00fd \u00da\u0159ad pro l\u00e9ky a potraviny (FDA) p\u0159ed u\u017e\u00edv\u00e1n\u00edm p\u0159\u00edpravku Wegovy, p\u0159i kter\u00e9m s\u00e1m v\u00fdrobce uzn\u00e1v\u00e1, \u017ee s n\u00edm nen\u00ed n\u011bco v po\u0159\u00e1dku, pokud jde o riziko rakoviny.<\/span><\/p>\n

Ukazuje se, \u017ee velk\u00fdm faktorem \u00fasp\u011bchu spole\u010dnosti Novo Nordisk jako farmaceutick\u00e9 firmy je pr\u00e1v\u011b semaglutid.\u00a0Spole\u010dnost je nyn\u00ed druhou nejhodnotn\u011bj\u0161\u00ed v Evrop\u011b, zaost\u00e1v\u00e1 jen za francouzskou skupinou luxusn\u00edho zbo\u017e\u00ed LVMH.<\/span><\/p>\n

Nejnov\u011bj\u0161\u00ed zpr\u00e1vy o ko\u0161t\u011bti toxick\u00fdch l\u00e9\u010div naleznete na str\u00e1nce\u00a0\u00a0<\/span>BadMedicine.news<\/span><\/a> .<\/span><\/p>\n

Autor: Ethan Huff, Zdroj:\u00a0<\/span>naturalnews.com<\/span><\/a>\u00a0<\/span><\/p>\n

 <\/p>\n

\"\"<\/a><\/p>\n

 <\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Evropsk\u00e1 l\u00e9kov\u00e1 agentura (EMA) vydala tento t\u00fdden upozorn\u011bn\u00ed o bezpe\u010dnosti l\u00e9k\u016f p\u0159edepisovan\u00fdch na cukrovku 2….<\/p>\n","protected":false},"author":2,"featured_media":31183,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[7],"tags":[5355,132,1453,1366,1402],"_links":{"self":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts\/31182"}],"collection":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/comments?post=31182"}],"version-history":[{"count":1,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts\/31182\/revisions"}],"predecessor-version":[{"id":31184,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/posts\/31182\/revisions\/31184"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/media\/31183"}],"wp:attachment":[{"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/media?parent=31182"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/categories?post=31182"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.infokuryr.cz\/n\/wp-json\/wp\/v2\/tags?post=31182"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}